Active enantiomer of AMPA (EC50 = 3.5 μM).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 186.17. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.37 mL||26.86 mL||53.71 mL|
|5 mM||1.07 mL||5.37 mL||10.74 mL|
|10 mM||0.54 mL||2.69 mL||5.37 mL|
|50 mM||0.11 mL||0.54 mL||1.07 mL|
References are publications that support the biological activity of the product.
Falch et al (1998) Heteroaryl analogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry, and structure-activity relationships. J.Med.Chem. 41 2513 PMID: 9651156
Hansen et al (1983) Enzymic resolution and binding to rat brain membranes of the glutamic acid agonist α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. J.Med.Chem. 26 901 PMID: 6133955
Lauridsen et al (1985) Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors. J.Med.Chem. 28 668 PMID: 2859375
If you know of a relevant reference for (S)-AMPA, please let us know.
View Related Products by Product Action
Keywords: (S)-AMPA, (S)-AMPA supplier, Selective, AMPA, agonists, Glutamate, Receptors, iGluR, Ionotropic, 0254, Tocris Bioscience
10 Citations for (S)-AMPA
Citations are publications that use Tocris products. Selected citations for (S)-AMPA include:
Langner et al (2017) Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms. Neurochem Res 42 838 PMID: 27444613
Pooler et al (2013) Physiological release of endogenous tau is stimulated by neuronal activity. J Neurosci 14 389 PMID: 23412472
Oh et al (2012) Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. EMBO Rep 7 e47846 PMID: 23110111
Underhill (2007) Hypoxic injury of isolated axons is independent of ionotropic glutamate receptors. Neurobiol Dis 25 284 PMID: 17071096
Lussier et al (2011) Activity-dependent ubiquitination of the AMPA receptor subunit GluA2. Proc Natl Acad Sci U S A 31 3077 PMID: 21414928
Limon et al (2007) Properties of GluR3 receptors tagged with GFP at the amino or carboxyl terminus. Neuroreport 104 15526 PMID: 17881566
Park et al (2016) Involvement of AMPA Receptor and Its Flip and Flop Isoforms in Retinal Ganglion Cell Death Following Oxygen/Glucose Deprivation. Invest Ophthalmol Vis Sci 57 508 PMID: 26868754
Jackson et al (2010) Control of cerebellar long-term potentiation by P-Rex-family guanine-nucleotide exchange factors and phosphoinositide 3-kinase. PLoS One 5 e11962 PMID: 20694145
Fairless et al (2013) Membrane potential measurements of isolated neurons using a voltage-sensitive dye. PLoS One 8 e58260 PMID: 23516458
Bell et al (2015) Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. PLoS One 6 7066 PMID: 25967870
Do you know of a great paper that uses (S)-AMPA from Tocris? Please let us know.
Reviews for (S)-AMPA
There are currently no reviews for this product. Be the first to review (S)-AMPA and earn rewards!
Have you used (S)-AMPA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.